You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema
SBC: Covenant Therapeutics LLC Topic: NHLBIDESCRIPTION (provided by applicant): The objective of this proposal is to exploit a newly discovered anti-inflammatory function involving the aminopeptidase activity of the leukotriene A4 hydrolase for the treatment of pulmonary emphysema. The leukotrieneA4 hydrolase is a dual-functioning enzyme with dichotomously opposing functions. As an epoxide hydrolase, it catalyzes the conversion of leukotri ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Remote focusing through spatial light modulation for multifocal multiphoton micro
SBC: BOULDER NONLINEAR SYSTEMS, INC. Topic: NIMHDESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Position tracking and mobility assessment system for indoor monitoring of elders
SBC: EMBEDRF LLC Topic: NIADESCRIPTION (provided by applicant): The goal of this project is to develop and evaluate a position tracking and mobility assessment system that will enable the elderly to live longer and more safely at home or in an assisted living facility. The ability to move is a critical function tat underlies the quality of life for the elderly. Changes in mobility such as speed of walking have been shown to ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Naloxone Nasal Spray Development
SBC: ANTIOP, INC. Topic: NIDADESCRIPTION: The following proposal is a follow-on Phase 2 b application from our initial proposal (1-R42 DA 030001). U.S. drug overdose deaths, mostly commonly from opioids, now exceed deaths from automobile accidents. There is a significant unmet medical need to provide additional pharmacologic options for treatment of opioid overdose. Emergency medical service personnel would prefer a non- inj ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Automated point-of-care identification of innocent Still's murmur in children
SBC: AUSCULTECH DX LLC Topic: NHLBIPROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low-cost, point-of-care, mobile device-based technology for automated identification of Stillandapos;s murmur, the most common innocent (benign and harmless) heart murmur of childhood. This novel technology could reduce the current rate of over half a million children unnecessarily referred to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques
SBC: Navidea Biopharmaceuticals, Inc. Topic: NHLBIMyocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
The Daily Progress System- A Recovery Support Tool to Reduce Health Disparities in Outpatient Substance Use Treatment
SBC: COG ANALYTICS, LLC Topic: 102ABSTRACTSubstance use disordersSUDsincluding opioid use disorderscontinue to be one of the most serious public health issues in the USleading to negative physical and mental health problemsfamily disruptionand premature deathAfrican Americans with drug use histories that are under criminal justice supervision are particularly vulnerable to experiencing the negative consequences associated with SUD ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health